CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

That is the good news. The risk, however, is that competition is rising. Telix Pharmaceuticals ( TLX) offers ILLUCCIX, which ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

The post Big, Beautiful Bill Finds Its Opponents appeared first on Reason.com.